Health ❯ Healthcare ❯ Oncology

Melanoma

Advanced Melanoma Adjuvant Therapy Advanced Melanoma Treatments BRAF-targeted Therapy Vaccines Tumor-Infiltrating Lymphocytes Treatment Options Immunotherapy Oncolytic Therapies T-Cell Receptor T-Cells BRAF V600 Mutation Immune Checkpoint Inhibitors Chimeric Antigen Receptor T-Cells Diagnosis Neoadjuvant Therapy Treatment Protocols Lung Cancer Immunotherapy Resistance

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

The decision underscores the FDA’s insistence on well‑controlled efficacy data over single‑arm results.

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

TIM‑3 Triplet Therapy Shows Promise in Immunotherapy‑Resistant Melanoma Models

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy